

# Rodrigo A Bressan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10767563/publications.pdf>

Version: 2024-02-01

32  
papers

2,302  
citations

331670

21  
h-index

395702

33  
g-index

33  
all docs

33  
docs citations

33  
times ranked

3924  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. <i>JAMA Psychiatry</i> , 2021, 78, 77.	11.0	57
2	Psychotic-like Experiences and Common Mental Disorders in Childhood and Adolescence: Bidirectional and Transdiagnostic Associations in a Longitudinal Community-based Study. <i>Schizophrenia Bulletin Open</i> , 2021, 2, .	1.7	10
3	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	7.9	23
4	A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice. <i>Schizophrenia Research</i> , 2020, 218, 195-200.	2.0	16
5	Population neuroscience: challenges and opportunities for psychiatric research in low- and middle-income countries. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 442-448.	1.7	5
6	Childhood trauma and adolescent psychotic experiences in a community-based cohort: The potential role of positive attributes as a protective factor. <i>Schizophrenia Research</i> , 2019, 205, 23-29.	2.0	11
7	Component mechanisms of executive function in schizophrenia and their contribution to functional outcomes. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 22-30.	1.7	12
8	Polygenic Risk Score for Alzheimer’s Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life. <i>American Journal of Psychiatry</i> , 2018, 175, 555-563.	7.2	75
9	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
10	Ventral Striatum Functional Connectivity as a Predictor of Adolescent Depressive Disorder in a Longitudinal Community-Based Sample. <i>American Journal of Psychiatry</i> , 2017, 174, 1112-1119.	7.2	130
11	A general psychopathology factor (P factor) in children: Structural model analysis and external validation through familial risk and child global executive function.. <i>Journal of Abnormal Psychology</i> , 2017, 126, 137-148.	1.9	189
12	Testing Measurement Invariance across Groups of Children with and without Attention-Deficit/Hyperactivity Disorder: Applications for Word Recognition and Spelling Tasks. <i>Frontiers in Psychology</i> , 2017, 8, 1891.	2.1	6
13	Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia?. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 121-126.	1.7	27
14	Can neuroimaging be used to predict the onset of psychosis?. <i>Lancet Psychiatry</i> , the, 2015, 2, 1117-1122.	7.4	36
15	Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 84-89.	1.8	16
16	The joint structure of major depression, anxiety disorders, and trait negative affect. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 285-292.	1.7	13
17	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.3	229
18	Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia. <i>Physiology and Behavior</i> , 2014, 129, 194-198.	2.1	49

#	ARTICLE	IF	CITATIONS
19	Management of schizophrenia: clinical experience with asenapine. <i>Journal of Psychopharmacology</i> , 2013, 27, 14-22.	4.0	10
20	Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1376-1382.	3.1	84
21	Structural validity and reliability of the Positive and Negative Affect Schedule (PANAS): Evidence from a large Brazilian community sample. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, 169-172.	1.7	69
22	Violence and post-traumatic stress disorder in Sao Paulo and Rio de Janeiro, Brazil: the protocol for an epidemiological and genetic survey. <i>BMC Psychiatry</i> , 2009, 9, 34.	2.6	38
23	Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancyâ€”a [123I]CNS-1261 SPET study. <i>Psychopharmacology</i> , 2008, 197, 401-408.	3.1	89
24	Ketamine displaces the novel NMDA receptor SPET probe [123I]CNS-1261 in humans in vivo. <i>Nuclear Medicine and Biology</i> , 2006, 33, 239-243.	0.6	34
25	Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. <i>Psychopharmacology</i> , 2005, 180, 664-669.	3.1	21
26	Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. <i>Psychopharmacology</i> , 2004, 175, 367-373.	3.1	38
27	A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. <i>Nuclear Medicine and Biology</i> , 2004, 31, 155-164.	0.6	30
28	Evaluation of NMDA Receptors in Vivo in Schizophrenic Patients with [123I]CNS 1261 and SPET. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 364-367.	3.8	13
29	Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. <i>Psychiatry Research</i> , 2003, 117, 47-56.	3.3	56
30	Kinetic modelling of [123I]CNS 1261â€”a potential SPET tracer for the NMDA receptor. <i>Nuclear Medicine and Biology</i> , 2003, 30, 441-454.	0.6	46
31	Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients. <i>American Journal of Psychiatry</i> , 2003, 160, 1413-1420.	7.2	112
32	Typical antipsychotic drugs â€” D2 receptor occupancy and depressive symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2002, 56, 31-36.	2.0	71